Paquinimod

DB13118InvestigationalSmall molecule

Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively... Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide.

Formula / weight: C₂₁H₂₂N₂O₃ · 350.418 g/mol (avg)
Code names: ABR-215757

Resolves to

Compound

UNIIHB76GLG27VCAS248282-01-1ChEMBLCHEMBL67776PubChem54684617

Structure

InChIKeyDIKSYHCCYVYKRO-UHFFFAOYSA-NSMILESCCN(C(=O)C1=C(O)C2=C(CC)C=CC=C2N(C)C1=O)C1=CC=CC=C1

Targets

P06702S100A9

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Paquinimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account